Logos Global Management LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Logos Global Management LP reported 53 stock positions worth $892.7 million. Its top holding was Ideaya Biosciences (IDYA) at 7.5% of the portfolio, followed by Structure Therapeutics (GPCR, 6.1%) and Revolution Medicines (RVMD, 6.1%). Compared with Q2 2024, it opened 14 new positions, sold out of 11, added to 9 and reduced 18. The biggest buy was a new position in Vaxcyte (PCVX) and the biggest sale an exit from Argenx SE - ADR (ARGX).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $892.7M (Q3 2024)
- SEC Filing
- 0001172661-24-005030 ↗ filed Nov 14, 2024
Holdings Value
Holdings 53 stocks · $892.7M
| IDYA Ideaya Biosciences Inc. | 7.45% | 2,100,000 | $66.5M | Add +23.5% |
| GPCR Structure Therapeutics Inc. | 6.15% | 1,250,000 | $54.9M | Add +13.6% |
| RVMD Revolution Medicines Inc. | 6.10% | 1,200,000 | $54.4M | No change |
| IRON Disc Medicine Inc. | 5.15% | 935,000 | $45.9M | Add +1.1% |
| JANX Janux Therapeutics Inc. | 5.09% | 1,000,000 | $45.4M | Add +33.3% |
| OLMA Olema Pharmaceuticals Inc. | 4.29% | 3,208,875 | $38.3M | No change |
| PCVX Vaxcyte Inc. | 3.84% | 300,000 | $34.3M | New |
| IMVT Immunovant Inc. | 3.51% | 1,100,000 | $31.4M | Add +91.3% |
| CLDX Celldex Therapeutics Inc. | 3.43% | 900,000 | $30.6M | New |
| OCUL Ocular Therapeutix Inc. | 3.41% | 3,500,000 | $30.4M | Reduce -32.0% |
| IONS Ionis Pharmaceuticals Inc. | 3.37% | 750,000 | $30.0M | Add +150.0% |
| ERAS Erasca Inc. | 3.33% | 10,900,000 | $29.8M | Add +84.8% |
| MRUS Merus NV | 3.22% | 575,000 | $28.7M | Reduce -32.4% |
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 2.58% | 800,000 | $23.0M | New |
| AKRO Akero Therapeutics Inc. | 2.57% | 800,000 | $23.0M | No change |
| DSGN Design Therapeutics Inc. | 2.54% | 4,217,627 | $22.7M | Reduce -16.2% |
| VERA Vera Therapeutics Inc. | 2.48% | 500,000 | $22.1M | Reduce -47.4% |
| COGT Cogent Biosciences Inc. | 2.42% | 2,000,000 | $21.6M | New |
| CYTK Cytokinetics Inc. | 2.37% | 400,000 | $21.1M | New |
| BCAX Bicara Therapeutics Inc. | 2.28% | 800,000 | $20.4M | New |
| SRPT Sarepta Therapeutics Inc. | 2.10% | 150,000 | $18.7M | No change |
| ANNX Annexon Inc. | 1.72% | 2,600,000 | $15.4M | Reduce -21.2% |
| TVTX Travere Therapeutics Inc. | 1.72% | 1,100,000 | $15.4M | New |
| ELVN Enliven Therapeutics Inc. | 1.42% | 495,000 | $12.6M | Reduce -16.8% |
| BEAM Beam Therapeutics Inc. | 1.37% | 500,000 | $12.3M | New |
| EWTX Edgewise Therapeutics Inc. | 1.35% | 450,000 | $12.0M | New |
| BCYC Bicycle Therapeutics PLC-ADR | 1.27% | 500,000 | $11.3M | New |
| YMAB Y-Mabs Therapeutics Inc. | 1.18% | 800,000 | $10.5M | New |
| ARVN Arvinas Inc. | 1.10% | 400,000 | $9.9M | New |
| TRVI Trevi Therapeutics Inc. | 1.03% | 2,750,000 | $9.2M | Reduce -1.8% |
| NUVL Nuvalent Inc. Class A | 0.86% | 75,000 | $7.7M | Reduce -61.5% |
| CMPS Compass Pathways PLC | 0.82% | 1,159,030 | $7.3M | No change |
| ORKA Oruka Therapeutics Inc. | 0.71% | 257,330 | $6.3M | New |
| RCKT Rocket Pharmaceuticals Inc. | 0.67% | 325,000 | $6.0M | Reduce -7.1% |
| SYRE Spyre Therapeutics Inc. | 0.66% | 200,000 | $5.9M | Reduce -65.2% |
| DYN Dyne Therapeutics Inc. | 0.64% | 160,000 | $5.7M | Reduce -39.6% |
| ATXS Astria Therapeutics Inc. | 0.62% | 500,000 | $5.5M | No change |
| HELP Cybin Inc. | 0.60% | 600,000 | $5.3M | Reduce -42.6% |
| ENGN Engene Holdings Inc. | 0.59% | 800,000 | $5.3M | Reduce -33.3% |
| AVTX Avalo Therapeutics Inc. | 0.57% | 539,079 | $5.1M | No change |
| LCTX Lineage Cell Therapeutics Inc. | 0.51% | 5,000,000 | $4.5M | Add +6.4% |
| RAPP Rapport Therapeutics Inc. | 0.46% | 208,910 | $4.1M | No change |
| SLN Silence Therapeutics PLC-ADR | 0.41% | 200,000 | $3.6M | Reduce -86.5% |
| ATYR Atyr Pharma Inc. | 0.39% | 2,000,000 | $3.5M | Reduce -33.3% |
| NXTC Nextcure Inc. | 0.38% | 2,500,000 | $3.4M | No change |
| ADVM Adverum Biotechnologies Inc. | 0.33% | 416,666 | $2.9M | No change |
| ARTV Artiva Biotherapeutics Inc. | 0.24% | 145,089 | $2.1M | New |
| UNICYCIVE THERAPEUTICS INC | 0.23% | 5,078,927 | $2.1M | Add +46.4% |
| ALLK Allakos LLC | 0.21% | 2,900,000 | $1.9M | No change |
| NMRA Neumora Therapeutics Inc. | 0.15% | 100,000 | $1.3M | Reduce -66.7% |
| IOBTQ Io Biotech Inc. | 0.06% | 493,827 | $519K | No change |
| SKYE Skye Bioscience Inc. | 0.04% | 100,000 | $391K | Reduce -92.3% |
| BOLD Boundless Bio Inc. | 0.02% | 58,903 | $204K | Reduce -50.0% |
Options reported separately and not counted above: APLS calls ($28.8M), FULC calls ($5.4M).
Portfolio Sells Q2 2024 → Q3 2024
| ARGX Argenx SE - ADR | Sold out | 0.00% | −6.69 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −3.80 |
| XNCR Xencor Inc. | Sold out | 0.00% | −3.27 |
| SLN Silence Therapeutics PLC-ADR | Reduce -86.5% | 0.41% | −2.82 |
| MRUS Merus NV | Reduce -32.4% | 3.22% | −2.58 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −1.77 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −1.68 |
| STOK Stoke Therapeutics Inc. | Sold out | 0.00% | −1.63 |
| VERA Vera Therapeutics Inc. | Reduce -47.4% | 2.48% | −1.48 |
| ELEV Elevation Oncology Inc. | Sold out | 0.00% | −1.20 |
| SKYE Skye Bioscience Inc. | Reduce -92.3% | 0.04% | −1.16 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −1.00 |
| RLAY Relay Therapeutics Inc. | Sold out | 0.00% | −0.98 |
| SYRE Spyre Therapeutics Inc. | Reduce -65.2% | 0.66% | −0.90 |
| NUVL Nuvalent Inc. Class A | Reduce -61.5% | 0.86% | −0.85 |
| ENGN Engene Holdings Inc. | Reduce -33.3% | 0.59% | −0.71 |
| HELP Cybin Inc. | Reduce -42.6% | 0.60% | −0.65 |
| OCUL Ocular Therapeutix Inc. | Reduce -32.0% | 3.41% | −0.65 |
| DYN Dyne Therapeutics Inc. | Reduce -39.6% | 0.64% | −0.43 |
| APLT Applied Therapeutics Inc. | Sold out | 0.00% | −0.31 |
| RNAC Cartesian Therapeutics Inc. | Sold out | 0.00% | −0.28 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -7.1% | 0.67% | −0.20 |
| NMRA Neumora Therapeutics Inc. | Reduce -66.7% | 0.15% | −0.19 |
| ELVN Enliven Therapeutics Inc. | Reduce -16.8% | 1.42% | −0.19 |
| ATYR Atyr Pharma Inc. | Reduce -33.3% | 0.39% | −0.14 |
| ANNX Annexon Inc. | Reduce -21.2% | 1.72% | −0.14 |
| BOLD Boundless Bio Inc. | Reduce -50.0% | 0.02% | −0.03 |
| TRVI Trevi Therapeutics Inc. | Reduce -1.8% | 1.03% | +0.07 |
| DSGN Design Therapeutics Inc. | Reduce -16.2% | 2.54% | +0.60 |
Portfolio Buys Q2 2024 → Q3 2024
| PCVX Vaxcyte Inc. | New | 3.84% | +3.84 |
| CLDX Celldex Therapeutics Inc. | New | 3.43% | +3.43 |
| LKFT Lakefront Biotherapeutic-ADR | New | 2.58% | +2.58 |
| COGT Cogent Biosciences Inc. | New | 2.42% | +2.42 |
| CYTK Cytokinetics Inc. | New | 2.37% | +2.37 |
| BCAX Bicara Therapeutics Inc. | New | 2.28% | +2.28 |
| IMVT Immunovant Inc. | Add +91.3% | 3.51% | +1.76 |
| ERAS Erasca Inc. | Add +84.8% | 3.33% | +1.73 |
| TVTX Travere Therapeutics Inc. | New | 1.72% | +1.72 |
| IONS Ionis Pharmaceuticals Inc. | Add +150.0% | 3.37% | +1.72 |
| JANX Janux Therapeutics Inc. | Add +33.3% | 5.09% | +1.47 |
| BEAM Beam Therapeutics Inc. | New | 1.37% | +1.37 |
| EWTX Edgewise Therapeutics Inc. | New | 1.35% | +1.35 |
| BCYC Bicycle Therapeutics PLC-ADR | New | 1.27% | +1.27 |
| YMAB Y-Mabs Therapeutics Inc. | New | 1.18% | +1.18 |
| GPCR Structure Therapeutics Inc. | Add +13.6% | 6.15% | +1.17 |
| ARVN Arvinas Inc. | New | 1.10% | +1.10 |
| ORKA Oruka Therapeutics Inc. | New | 0.71% | +0.71 |
| IDYA Ideaya Biosciences Inc. | Add +23.5% | 7.45% | +0.57 |
| IRON Disc Medicine Inc. | Add +1.1% | 5.15% | +0.34 |
| ARTV Artiva Biotherapeutics Inc. | New | 0.24% | +0.24 |
| UNICYCIVE THERAPEUTICS INC | Add +46.4% | 0.23% | +0.03 |
| LCTX Lineage Cell Therapeutics Inc. | Add +6.4% | 0.51% | −0.03 |
Options Activity Q2 2024 → Q3 2024
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 2,000,000 | $185.4Mbefore exit |
| SRPT Sarepta Therapeutics Inc. | call | Sold out | 500,000 | $79.0Mbefore exit |
| APLS Apellis Pharmaceuticals Inc. | call | Reduce -50.0% | 1,000,000 | $28.8M |
| GPCR Structure Therapeutics Inc. | call | Sold out | 450,000 | $17.7Mbefore exit |
| ANNX Annexon Inc. | call | Sold out | 1,500,000 | $7.3Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q2 2024 → Q3 2024
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | Sold out | 66,666 | $11Kbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |